Rexulti Approved for Depression, Schizophrenia Treatment

Home / Depression Counseling / Rexulti Approved for Depression, Schizophrenia Treatment

This past week, the U.S. Food and Drug Administration (FDA) approved Rexulti (brexpiprazole) as an adjunct therapy for the treatment of adults with major depressive disorder (MDD, also known as clinical depression) and for adults with schizophrenia. It is expected to be available to patients in August. Research demonstrating Rexulti’s clinical effectiveness was conducted on more than 4,300 patients, with four placebo-controlled studies (two each for depression and schizophrenia). “Schizophrenia and major depressive disorder can be disabling and can greatly disrupt day-to-day activities,” noted Dr. Mitchell Mathis, director of the

read more…

Click on the link for to know more about Depression Counseling

Published By: Psych Central – Saturday, 18 July, 2015

 

Leave a Reply

Your email address will not be published. Required fields are marked *